On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase […]

Govvi WOW! contains hidden ingredient 12/21/2023 Public Notification: Phentamene XT contains hidden drug ingredient 5/05/2023 Public Notification: NORF 20 contains hidden drug ingredients 5/01/2023 Public Notification: […]

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) […]

To encourage innovation and competition in the market for biological products and facilitate the development of biosimilars and interchangeable biosimilars, FDA has developed the Biosimilars Action […]

Office of Communications10001 New Hampshire AveHillandale Building, 4th FlSilver Spring, MD 20993 Toll Free (855) 543-3784 (301) 796-3400 Hours Available CDER Division of Drug Information

FDA classifies inspections based on a company’s state of compliance as acceptable or unacceptable with respect to CGMP requirements: No action indicated (NAI) classification indicates a facility […]

Patients often receive several types of informational documents with their prescription medication. These documents are intended to help patients take their drugs safely and effectively, help […]